Benzinga | Nov 24, 2020 05:42AM EST

Evercore ISI Group Initiates Coverage On BioCryst Pharmaceuticals with Outperform Rating, Announces Price Target of $12

Evercore ISI Group analyst Liisa Bayko initiates coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Outperform rating and announces Price Target of $12.